ECT, TMS, and Esketamine: Mapping Options for TRD

Review Compares ECT, TMS, and Esketamine for Hard-to-Treat Depression

A psychiatrist writing for Psychiatric Times published a review on October 5, 2026, walking through interventional options for treatment-resistant depression (TRD), a term clinicians use when a patient's depression has not responded to at least two adequate trials of different antidepressant medications. According to the Psychiatric Times review, the author first examined structured care settings, inpatient hospitalization, partial hospitalization programs (PHP), and intensive outpatient programs (IOP), before describing how electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) work. Esketamine, the FDA-approved nasal spray brand name Spravato, rounds out the three interventional treatments named in the piece's title.

For readers researching ketamine-based depression care, this review is useful less for what it says about ketamine specifically and more for where it places esketamine within the broader hierarchy of TRD treatment. Understanding that hierarchy helps explain why a clinician might recommend one option over another, and where off-label low-dose ketamine therapy sits relative to the FDA-cleared pathway.

What ECT, TMS, and Esketamine Actually Do

ECT involves delivering a controlled electrical current to the brain under general anesthesia to induce a brief, therapeutic seizure. It remains the treatment with the longest track record for severe or treatment-resistant depression and is typically reserved for patients who need rapid symptom relief or who have not responded to multiple medication trials. TMS uses magnetic pulses, delivered through a coil placed against the scalp, to stimulate specific regions of the prefrontal cortex associated with mood regulation. It does not require anesthesia and is usually delivered as a series of outpatient sessions over several weeks. Esketamine is the S-enantiomer of ketamine, administered as a nasal spray under direct medical supervision, and is FDA-approved specifically for treatment-resistant depression in combination with an oral antidepressant.

The review's structure, moving from inpatient and outpatient program levels down through ECT, TMS, and esketamine, reflects how many psychiatrists stage care: start with the least invasive option that matches illness severity, and escalate when response is inadequate. That staging logic matters for anyone comparing esketamine to other ketamine-based approaches, because it is built around FDA-labeled indications and insurance-reimbursable pathways, not around off-label protocols.

Where Off-Label Low-Dose Ketamine Fits In

The review's framing is a reminder that off-label ketamine occupies a gray zone relative to the three options it names. ECT, TMS, and esketamine all have FDA clearance or a long regulatory and research history specific to TRD, which is why they appear in a structured psychiatric treatment review in the first place. Off-label low-dose ketamine, by contrast, is typically prescribed under a physician's clinical judgment, often outside psychiatric hospital systems, and without the same standardized dosing protocols or insurance infrastructure.

That does not mean off-label ketamine lacks evidence. A substantial body of clinical research, separate from this review, has studied intravenous and intramuscular ketamine for depression, and many of those findings informed esketamine's eventual FDA approval. But the research base for the specific off-label protocols used at independent ketamine clinics varies widely in dose, frequency, and monitoring standards from clinic to clinic, which is a different situation than a single FDA-labeled product with a fixed dosing schedule.

The practical implication is that patients comparing options should not assume interchangeability. A psychiatrist recommending ECT, TMS, or esketamine is working from guidelines tied to a specific diagnosis code and treatment history. A ketamine clinic offering low-dose infusions is generally working from off-label clinical experience and published research on ketamine's antidepressant mechanism, which can still be reasonable care, but it carries a different evidentiary and regulatory footing worth understanding before starting.

What This Means If You're Weighing Ketamine Therapy

If you have tried multiple antidepressants without adequate relief, treatment-resistant depression guidelines generally suggest working through options in order of invasiveness and evidence strength, as this review reflects. Ask any prescriber, whether they're offering esketamine or off-label low-dose ketamine, these questions before starting:

1. Is this treatment FDA-approved for my condition, or is it being used off-label? Both can be appropriate, but you should know which one you're getting.
2. What dosing protocol and monitoring will be used, including blood pressure checks and post-session observation, since ketamine and esketamine both carry dissociative and cardiovascular effects during and shortly after dosing?
3. How does this option fit with, or replace, structured programs like PHP or IOP if your depression is severe enough to need that level of support?
4. What is the expected timeline to response, and what does a maintenance plan look like if the initial course works?

None of these questions have a universal answer, and the Psychiatric Times piece does not attempt to rank ECT, TMS, and esketamine against off-label ketamine protocols directly. Readers should treat this review as useful context for understanding where esketamine sits in standard psychiatric care, and should discuss their specific history and symptom severity with a psychiatrist before choosing between FDA-approved and off-label ketamine-based routes.